CClinicalTrials.gg
Not yet recruitingNCT07555821Updated Apr 29, 2026

Improving Postoperative Analgesia After Functional Endoscopic Surgery

A Phase 2/3 interventional study of Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine in Pain Management After Functional Endoscopic Sinuscopy, sponsored by South Egypt Cancer Institute. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by South Egypt Cancer Institute · Phase 2/3, Interventional, and Supportive care

Phase
Phase 2/3
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Improving postoperative analgesia after functional endoscopic surgery: Sphenopalatine ganglion block versus soaked nasal packing using bupivacaine and dexmedetomidine

02

Conditions studied

  • Pain Management After Functional Endoscopic Sinuscopy
03

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age 18 - 60 years
  2. ASA physical status I -II
  3. Patients scheduled for elective FESS

Exclusion criteria

Exclusion Criteria:

  1. Allergy to drugs used
  2. Coagulopathy or anticoagulant therapy
  3. Severe cardiovascular, renal and hepatic disease
  4. Chronic opioid use Pregnancy
04

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    group a

    Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine

    Drug: Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine

  • Experimental
    druop b

    Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine

    Drug: Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine

Interventions

  • DrugSphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine

    Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine

05

What researchers measure

Primary outcomes

  1. effectiveness of SPGB with bupivacaine and dexmedetomidine for postoperative analgesia

    Numeric rating scale for pain will be assessed and recorded within the first 24 hours where 1 means the worst pain and 10 means no pain. Total rescue analgesia in 24 H when Numeric rating scale ≥ 4 was recorded and the first time when it was given will be recorded.

    Time frame: 6 months

06

Study locations

1 site
  • Assiut university hospital
    Asyut, 161715, Egypt
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07555821
Lead sponsor
South Egypt Cancer Institute
Responsible party
Ahmed Kamal Sayed (anesthesia consultant, Assiut University) — Principal investigator
First posted
Apr 29, 2026
Start date
Apr 15, 2026 (estimated)
Primary completion
Oct 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Apr 29, 2026

Study contacts

Sara Mansour Mansour
Contact
saram@aun.edu.eg
1061092528 ext. 0020
Ahmed Kamal Attia
Contact
ahmedkamal86anathesia@gmail.com
1010677881 ext. 0020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion